Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): ##STR00001##
or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q.sub.1, Q.sub.2, Z, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): ##STR00001##
or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q.sub.1, Q.sub.2, Z, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

A preparative method for carboxylic acids is disclosed in the present invention. The method is characterized in that: compounds (II) are reacted in the presence of hydrogen peroxide and base to produce target products (I), as represented by the following reaction scheme: wherein R.sup.1 is aryl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, thiadiazolyl, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and hydrogen; R.sup.2 is alkoxycarbonyl, alkylaminocarbonyl, aminocarbonyl, alkylthiolcarbonyl, cyano, sulfonyl, sulfinyl, carbonyl, aldehyde, carboxyl, nitro, alkyl and hydrogen; R.sup.3 is alkoxycarbonyl, alkyl amido carbonyl, aminocarbonyl, cyano, sulfonyl, sulfinyl, carbonyl, carboxyl and nitro. The present invention has the following main benefits: cheap and readily available starting materials, safe processes, high yield, good quality, which facilitates industrial production.

A preparative method for carboxylic acids is disclosed in the present invention. The method is characterized in that: compounds (II) are reacted in the presence of hydrogen peroxide and base to produce target products (I), as represented by the following reaction scheme: wherein R.sup.1 is aryl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, thiadiazolyl, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and hydrogen; R.sup.2 is alkoxycarbonyl, alkylaminocarbonyl, aminocarbonyl, alkylthiolcarbonyl, cyano, sulfonyl, sulfinyl, carbonyl, aldehyde, carboxyl, nitro, alkyl and hydrogen; R.sup.3 is alkoxycarbonyl, alkyl amido carbonyl, aminocarbonyl, cyano, sulfonyl, sulfinyl, carbonyl, carboxyl and nitro. The present invention has the following main benefits: cheap and readily available starting materials, safe processes, high yield, good quality, which facilitates industrial production.

An object of the invention is to provide a compound that can be utilized as an antiviral agent, in particular as an anti-RNA viral agent, and especially as an anti-RS viral agent. The invention provides a compound indicated by Formula (1), wherein R1 each independently represent hydrogen, halogen, hydroxyl, amino, carboxyl, C1-C6 alkyl, C1-C6 alkoxyl, C1-C6 halogenoalkyl, C1-C6 alkoxycarbonyl, C1-C6 alkylamino, C2-C5 alkenyl, C3-C6 cycloalkyl, or optionally substituted aryl; R2 each independently represent hydrogen, C1-C6 alkyl, C1-C6 halogenoalkyl, C2-C5 alkenyl, C3-C6 cycloalkyl, optionally substituted aryl or heterocyclic group; and one or more R1 may be present in the same ring, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture of these. The compounds provided by the invention are useful as drugs for the prevention or treatment of infectious diseases by virus, especially RS virus, and in particular infectious diseases in the lower airways (e.g., bronchiolitis, pneumonia, etc.).

Provided is a method for manufacturing a mesoporous inorganic oxide, which includes preparing a mixture of a metal salt selected from the group consisting of at least one kind of alkali metal-containing compound, at least one kind of alkaline earth metal-containing compound, and any combination thereof and an amorphous inorganic oxide; sintering the mixture of a metal salt and an amorphous inorganic oxide; and removing the metal salt contained in the sintered mixture, and a mesoporous inorganic oxide that is manufactured by the above method and is composed of an aggregate of inorganic oxide particles having a size of from 2 nm to 5 nm.

According to the present invention, it is possible to provide a method for manufacturing a mesoporous inorganic oxide which has a simplified manufacturing process, has a short period of manufacturing time of about 1 day, does not generate secondary environmental contaminants to be environmentally friendly, and enables mass production, and a mesoporous inorganic oxide which has a dramatically decreased particle size and thus has an increased specific surface area and increased active sites.

Provided is a method for manufacturing a mesoporous inorganic oxide, which includes preparing a mixture of a metal salt selected from the group consisting of at least one kind of alkali metal-containing compound, at least one kind of alkaline earth metal-containing compound, and any combination thereof and an amorphous inorganic oxide; sintering the mixture of a metal salt and an amorphous inorganic oxide; and removing the metal salt contained in the sintered mixture, and a mesoporous inorganic oxide that is manufactured by the above method and is composed of an aggregate of inorganic oxide particles having a size of from 2 nm to 5 nm.

According to the present invention, it is possible to provide a method for manufacturing a mesoporous inorganic oxide which has a simplified manufacturing process, has a short period of manufacturing time of about 1 day, does not generate secondary environmental contaminants to be environmentally friendly, and enables mass production, and a mesoporous inorganic oxide which has a dramatically decreased particle size and thus has an increased specific surface area and increased active sites.

The present invention relates to compounds that have ultraviolet light absorbing properties, and which can also have mesogenic properties. The present invention also relates to compositions that include one or more such compounds, and to articles of manufacture that include one or more such compounds, such as optical elements that include an optical substrate and a layer that includes at least one compound of the present invention.

Pro-fragrances may have the formula (I) as disclosed herein. Compositions may include the pro-fragrances, such as a laundry product, a home care product, and an insect repellant. A method for preparing the compound of formula (I) are also disclosed. Such pro-fragrances increase the longlastingness of a fragrance, the stability of a fragrance, and the adhesion of a fragrance.

Pro-fragrances may have the formula (I) as disclosed herein. Compositions may include the pro-fragrances, such as a laundry product, a home care product, and an insect repellant. A method for preparing the compound of formula (I) are also disclosed. Such pro-fragrances increase the longlastingness of a fragrance, the stability of a fragrance, and the adhesion of a fragrance.